Jeff Roth’s Post

New article in Drugs in Context A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement petra staubach, Andreas Körber, Ralph M Trüeb, Caroline Mann, Praxis Dr. Med. Ralph Von Kiedrowski Narrative review evaluating data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate to treat patients with psoriasis and scalp involvement. #drugsincontext #dermatology #psoriasis #pharmacology https://lnkd.in/daF-6k_X

Atracurium Besilate is an API which is non-depolarizing neuromuscular blocker used to facilitate endotracheal intubation and relax skeletal muscles during surgery which works by blocking chemical messengers in the brain that are responsible for rigidity, inflammation or swelling. It effectively relieves muscle stiffness or spasm, thereby improving muscle movement. Although, during the manufacturing process, impurities can be formed, potentially impacting both the purity and potency of the final product. At Scintel, we ensure high standards and offer a diverse range of products to meet your needs. To explore our full selection, please visit https://lnkd.in/dmNdnMwe #scintelpharma #clinicalresearch #research #pharmaceutical #healthcare #drugs #antibiotics #pharmaceuticalstandards #referencestandards #drugdiscovery #drugdevelopment #analyticalstandards #impurities #stableisotopes #methoddevelopment #impurityqualification #Pharmacodynamics #drugmanufacturing #usfda #DrugSafety #clinicaltrials #healthcare #healthcareinnovation #pharmamanufacturing #ndsri #atracuriumbesylateepimpurityc #atracurium #atracuriumbesylate #atracuriumimpurity #atracuriumbesylateimpurity

Big news in the pharmaceutical world! Johnson & Johnson has acquired the rights to an experimental skin disorder treatment for a whopping $1.25 billion. 🎊 🎆The drug, NM26, is being developed for atopic dermatitis, a chronic condition causing itchy and inflamed skin. 🎆 This move comes shortly after J&J's acquisition of Proteologix for their atopic dermatitis treatments. 🙌J&J is clearly placing a big bet on the future of atopic dermatitis treatment! This could be a major breakthrough for millions suffering from this condition. #healthcare #dermatology #pharmaceuticals #johnsonjohnson

#Abrocitinib shows potential as a valuable remedy for #prurigo nodularis and chronic #pruritus, according to recent findings. This treatment option presents promising results for individuals dealing with these conditions. Learn more about the positive impact of Abrocitinib in managing prurigo nodularis and chronic pruritus. #Dermatology #MedicalResearch https://buff.ly/3RowtQZ

🔬 Science Corner #5: 👽 The Protease Predator 🧫 Our CYT-108 biopharmaceutical acts like a molecular predator, stalking and ensnaring the enzymes that chew up cartilage in OA. Here's how it works. Cytonics is on a mission to rid the world of osteoarthritis (OA) once and for all with our first-in-class biopharmaceutical, dubbed “CYT-108,” that attacks the disease at the molecular level. Unlike currently available palliative therapies which merely mask joint pain and inflammation (like NSAIDs and corticosteroids), CYT-108 is capable of addressing the root molecular cause of the disease, offering long-lasting relief through this “disease modification.” If approved by the FDA, CYT-108 will likely be the first and only disease-modifying therapy for OA, cracking open a $200-300B global market and forever changing the health and happiness of over 600M suffering people worldwide. Learn all about it... https://lnkd.in/eNbpvCC9 #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

📢 Shocking FDA - La Administración de Alimentos y Medicamentos Investigation: Obesity Drugs Linked to Suicidal Thoughts 📢 The US FDA is investigating the side effects of obesity drugs semaglutide and tirzepatide, following the European Medicines Agency's lead. The investigation focuses on the occurrence of "suicidal thoughts" after treatment with GLP-1 agonists such as Ozempic and Trulicity. The FDA is also looking into whether these drugs promote hair loss and aspiration during surgery. Previous studies have found no causal link between semaglutide and suicidal thoughts. Novo Nordisk and Eli Lilly and Company, the drug developers, are cooperating with the investigation. #BioprocessUpdates #FDAinvestigation #obesitydrugs #semaglutide #tirzepatide #GLP1agonists #suiciderisk #Ozempic #Trulicity #hairloss #aspiration #surgery #NovoNordisk #EliLilly #drugdevelopers #cooperation ▷ Read the full article here: 📎 https://lnkd.in/drEPqtKw

The final step in the platelet-rich plasma (PRP) journey is to gently agitate the collection tube so that the platelets are thoroughly resuspended into the patient’s plasma. Once collected with a syringe, the physician injects or applies the PRP to the target area. The patient’s own platelets then release growth factors at the site of the injury and begin the healing cascade. To follow the full PRP journey, stay tuned to this channel to see more advancements in orthobiologics: https://lnkd.in/gu_R4Jyf #prp #prptherapy #prptreatment #tropocells #sportsmedicine #orthopedics #healing #biologics #orthobiologics #transcend #recovery

Summary The article discusses the use of N-Acetylcarnosine (NAC) sustained drug delivery eye drops (Can-C™) to control signs of aging vision, such as glare sensitivity and cataracts, and improve the overall quality of vision. The study involved 75 patients with age-related cataracts and 72 non-cataract subjects, aged 54 to 78. Over a 9-month period, patients who used NAC eye drops reported significant improvements in glare sensitivity and visual acuity. The drops, containing a mucoadhesive cellulose-based compound, were well-tolerated and showed high efficacy in non-surgical treatment of cataracts, enhancing the visual function and quality of life for the aging population. Central Idea The central idea of the article is that N-Acetylcarnosine (NAC) sustained drug delivery eye drops are an effective, non-surgical solution for improving vision-related issues such as glare sensitivity and cataracts in older adults. This treatment significantly enhances the quality of vision and life, offering a promising alternative to cataract surgery. Solution The solution presented is the use of NAC eye drops, specifically designed and tested by Innovative Vision Products, Inc., for the prevention and treatment of age-related cataracts and glare sensitivity. The study demonstrated that regular use of these eye drops over nine months resulted in marked improvements in visual acuity and glare sensitivity without adverse effects, thus providing a viable and effective non-surgical treatment for age-related vision impairments. https://lnkd.in/dHaa8bTP

🔬 Science Corner #5: 👽 The Protease Predator 🧫 Our CYT-108 biopharmaceutical acts like a molecular predator, stalking and ensnaring the enzymes that chew up cartilage in OA. Here's how it works. Cytonics is on a mission to rid the world of osteoarthritis (OA) once and for all with our first-in-class biopharmaceutical, dubbed “CYT-108,” that attacks the disease at the molecular level. Unlike currently available palliative therapies which merely mask joint pain and inflammation (like NSAIDs and corticosteroids), CYT-108 is capable of addressing the root molecular cause of the disease, offering long-lasting relief through this “disease modification.” If approved by the FDA, CYT-108 will likely be the first and only disease-modifying therapy for OA, cracking open a $200-300B global market and forever changing the health and happiness of over 600M suffering people worldwide. Learn all about it... https://lnkd.in/eRBs4T-a #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

According to the latest research by Coherent Market Insights experts, The CAGR of the medical second opinion market is projected to be 16.3% from 2024 to 2031. Lack of awareness among patients and high cost of second opinion services are the major factors hampering the growth of the medical second opinion market.  Deep dive into detailed insights @ https://bit.ly/3Wt4Ppr #Neurological #Orthopedic #Medicalsecondopinion #CoherentMarketInsights #Keytrend #MarketDrivers #marketOpportunities #Pharmaceutical